/PRNewswire/ -- Evotec AG (Frankfurt Stock Exchange: EVT, TecDAX 30; Evotec) and ChemAxon, a software solutions provider for chemistry today announced Evotec's licensing of ChemAxon's complete product line, the successful implementation of selected ChemAxon toolkits and ongoing works to roll out further capabilities across Evotec's informatics network. Through the acquisition of ChemAxon's JChem platform, Evotec has built state of the art applications enabling it's scientists to perform and share key drug discovery and optimisation processes across all facilities, directly from their workbench. "Evotec are heavy users of Chemaxon's JChem products, and have integrated them into many of the advanced drug discovery software tools that we have developed internally. JChem tools allow us to develop highly intuitive desktop software available to all our scientists. The close working relationship with ChemAxon has been invaluable during our application development work," said Alistair Sedwell (IT Applications Team Leader), Evotec (UK) Ltd "Working with Evotec has been rewarding and has enabled us to support all of our clients with more relevant, accurate and powerful functionalities. We enjoy and look forward to continuing this collaboration," commented Ferenc Csizmadia, CEO Of ChemAxon. About ChemAxon ChemAxon is a leader in providing cheminformatics software development platforms and applications for the biotechnology, pharmaceutical and agrochemical industries. With core capabilities for structure visualization and management, property prediction, virtual synthesis, screening and drug design, ChemAxon focuses upon active interaction with users and software portability to create powerful, cost effective cross platform solutions and programming interfaces to power modern cheminformatics and chemical communication. For more information please visit www.chemaxon.com About Evotec AG Evotec is a leader in the discovery and development of novel small molecule drugs. Both through its own discovery programmes and through contract research partnerships, the Company is providing highest quality research results to its partners in the pharmaceutical and biotechnology industries. In proprietary projects, Evotec specialises in finding new treatments for diseases of the central nervous system (CNS). Evotec has three Phase I clinical programmes: EVT 201, a GABAA modulator for the treatment of insomnia, EVT 101, a subtype selective NMDA receptor antagonist for the treatment of Alzheimer's disease and EVT 301, a selective and reversible inhibitor of MAO-B for the treatment of Alzheimer's disease. In contract research, Evotec has established itself as the partner of choice for pharmaceutical and biotechnology companies worldwide. The Company provides innovative and often integrated solutions from drug target to clinic through an unmatched range of capabilities, including early stage assay development and screening through to medicinal chemistry and drug manufacturing. In 2005, Evotec has generated sales of EUR 80 million with approximately 600 people located in Hamburg, Germany and near Oxford and in Glasgow, UK. www.evotec.com
SOURCE ChemAxon Ltd.